Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Mast Cell Disorders
What is the overlap of POTS and Ehlers-Danlos with MCAS?
Related Questions
How do you counsel a patient on returning to the care of their PCP when a workup for MCAS has been unrevealing, but the patient insists that they have a mast cell disorder because they respond to antihistamine therapy?
Do you favor 24 hour urinary metabolites over random urine collection when screening for MCAS?
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
Is there any role for immunosuppressive/immunomodulatory therapy used off label for mast cell activation syndrome besides omalizumab?
Do you diagnose MCAS if a patient is concurrently on drugs known to cause non-specific mast cell degranulation?
Are you requiring markers other than LTE4 to be elevated to diagnose MCAS?
How do you interpret high C1q binding assay with otherwise normal C1q, C3, C4, CH50 in a patient with recurrent urticaria with positive ANA at high titer 1:1280, negative dsDNA, RNP, SM, normal CBC, CMP, UA, and UPCR.
How exhaustive (especially considering cost) should an immunological workup be for patients with extensive, recurrent, or deep seated Staph aureus infections without obvious immunocompromise (e.g. cancer, diabetes, steroids) or recurrent breaks in skin integrity?
Which types of patients do you treat with prolonged antibiotics before obtaining a CT sinus?
Does splitting the dose of a vaccine during an observed administration affect the efficacy of the vaccine response?
